DiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesInformation ScienceHealth CareGeographicals
Heparin AntagonistsHeparinAnticoagulantsMolecular WeightHeparin, Low-Molecular-WeightAtrial FibrillationNew ZealandStrokePrevalenceWarfarinAspirin
LMWHVitamin K AntagonistsFondaparinuxWarfarinUltra-low-moleculRivaroxabanAnticoagulationVenousPulmonaryAntiplatelet agentsAspirinDabigatranDOACPlateletDOACsOralInjectionsPatientsThromboprophylaxisConcomitantEnoxaparinDosePatient's2022ClotDeep vein thromXARELTOAPTTMedication2019ClotsComplicationsPregnancyExtremityClinical trialsAcuteIschemicInjectionExtremities
LMWH12
  • Except in overdoses, no utility exists in checking prothrombin time (PT) or activated partial thromboplastin time (aPTT) because aPTT does not correlate with anticoagulant effect of fractionated LMWH. (medscape.com)
  • Anticoagulants, such as low-molecular-weight heparin (LMWH), are known to be high-risk for adverse drug events. (ahrq.gov)
  • This cross-sectional study identified prescribing errors - primarily lack of dosage adjustment for body weight and/or renal function - among one-third of LMWH users admitted to one hospital over a five-month period. (ahrq.gov)
  • In 2011, the American College of Obstetricians and Gynecologists (ACOG) issued updated guidelines stating that for patients undergoing cesarean delivery with additional risk factors for clot or thromboembolism, protective (prophylactic) treatment with low molecular weight heparin (LMWH) a type of blood thinner should be considered. (druglib.com)
  • This is a multi-center, prospective, randomized controlled study to compare the proportion of patients that achieve the desired effect of LMWH (enoxaparin) thromboprophylaxis as measured by peak anti Xa level with weight based twice daily dosing versus standard fixed daily dosing. (druglib.com)
  • Preferred initial therapy for VTE in patients with cancer is low-molecular-weight heparin (LMWH)-based therapy over warfarin-based therapy or vitamin K antagonists (VKAs), according to guidelines from the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO), the American College of Chest Physicians (ACCP), and the National Cancer Comprehensive Network (NCCN). (oncologynurseadvisor.com)
  • Low-molecular-weight heparin (LMWH) is preferred as an effective and safe means for prophylaxis and treatment of VTE. (oncologynurseadvisor.com)
  • Low molecular weight heparin (LMWH) has better absorption after subcutaneous administration, and reduced protein binding results in improved bioavailability. (gponline.com)
  • LMWH possesses greater activity against activated factor X than prothrombin and has a more predictable anticoagulant effect. (gponline.com)
  • CONCLUSIONS: Strong recommendations included using patient self-management of international normalized ratio (INR) with home point-of-care INR monitoring for vitamin K antagonist therapy and against using periprocedural low-molecular-weight heparin (LMWH) bridging therapy. (cdc.gov)
  • Conditional recommendations included basing treatment dosing of LMWH on actual body weight, not using anti-factor Xa monitoring to guide LMWH dosing, using specialized anticoagulation management services, and resuming anticoagulation after episodes of life-threatening bleeding. (cdc.gov)
  • An increased incidence of thromboembolic events in hospitalised COVID-19 patients has been demonstrated despite the use of low-molecular-weight heparin (LMWH). (bvsalud.org)
Vitamin K Antagonists1
Fondaparinux2
  • Fondaparinux sodium is a synthetic anticoagulant that works by inhibiting factor Xa, a key component involved in blood clotting. (medscape.com)
  • Today there are many choices, such as one of the newer oral direct acting agents, intravenous heparin or subcutaneous low-molecular weight heparin or fondaparinux. (harvard.edu)
Warfarin10
  • Beginning warfarin treatment requires an additional non-oral anticoagulant, often injections of heparin. (wikipedia.org)
  • The warfarin doses before vitamin K were not significantly different between the 3 groups and, in fact, the absolute mean dose was lower in the GG group than in the GA or the AA group (3.23 mg, 4.52 mg, and 3.50 mg, respectively). (clotcare.com)
  • The warfarin doses after the addition of vitamin K also were not significantly different (mean daily doses of 4.05 mg, 4.86 mg, and 3.50 mg for GG, GA, and AA, respectively) - and the mean dose for the "resistant" group remained lower than the mean dose for the "average" (GA) group. (clotcare.com)
  • The risk of all-cause mortality was lower with all DOACs than with warfarin. (bmj.com)
  • The risk of intracranial bleeding was substantially lower for most DOACs compared with warfarin, whereas the risk of gastrointestinal bleeding was higher with some DOACs than warfarin. (bmj.com)
  • 3 Direct oral anticoagulants (DOACs), e.g. dabigatran or rivaroxaban, are generally favoured over vitamin K analogues, e.g. warfarin. (bpac.org.nz)
  • Although DOACs are associated with a lower risk of intracranial haemorrhage or fatal bleeding compared to warfarin, there is still concern over their potential bleeding risk. (eahp.eu)
  • It is sensible to use warfarin in low doses and gradually increase once every few weeks while concomitant administration with heparin is continued. (gponline.com)
  • In patients at high risk of acute thrombosis, once the indication has been confirmed, the traditional method of initiating therapy is administration of warfarin, with or without concurrent administration of heparin. (gponline.com)
  • One type of blood-thinning medicine called warfarin (Coumadin or Jantoven) may be started along with heparin. (medlineplus.gov)
Ultra-low-molecul1
Rivaroxaban5
  • Ideally, all patients who can benefit from using an anticoagulant, i.e. with a CHA 2 DS 2 -VASc score ≥ 2 for females or ≥ 1 for males, should either be prescribed a DOAC (i.e. dabigatran or rivaroxaban) or have a documented reason why not. (bpac.org.nz)
  • Direct Oral Anticoagulants (DOACs) such as apixaban, edoxaban, rivaroxaban and dabigatran, have been recognized by evidence-based treatment guidelines as the first-line option for the prevention of stroke in patients with non-valvular atrial fibrillation (AF) and the treatment of venous thromboembolism (VTE). (eahp.eu)
  • More recently a low dose of rivaroxaban has been licensed for the prevention of atherothrombotic events in patients after acute coronary syndrome (ACS), in patients with coronary artery disease (CAD) or peripheral artery disease (PAD). (eahp.eu)
  • RARITAN, N.J., July 8, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO ® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) - or blood clots - and similar rates of bleeding when compared to current standard anticoagulation therapy. (jnj.com)
  • Some doctors choose powerful anti-clotting drugs like heparin (Lovenox) and rivaroxaban (Xarelto), but it hasn't been clear whether these expensive prescription drugs work any better than cheap, readily available aspirin. (sciencedaily.com)
Anticoagulation3
  • Explain how the establishment of an antithrombotic stewardship programme within the hospital can improve adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications. (eahp.eu)
  • The Hospital Pharmacist as part of an antithrombotic stewardship programme needs to ensure adherence to anticoagulant guidelines to maximize the benefit of anticoagulation and minimize the complications. (eahp.eu)
  • For anticoagulation potency, the formation of the SP/protease protein complex and the associated non-specific polar interaction between the negatively and positively charged groups in the polysaccharide and protein is responsible for anticoagulant activity. (springer.com)
Venous8
  • The practical advantages and success of low-molecular-weight heparin administered subcutaneously without laboratory monitoring for the treatment of venous thromboembolism have prompted a number of randomized studies investigating the efficacy and safety of these agents in patients with acute coronary syndromes. (mcmaster.ca)
  • Direct oral anticoagulants or low-molecular-weight heparins for venous thromboembolism in patients with brain tumors. (ucsf.edu)
  • Several risk factors for developing venous thrombosis usually coexist in cancer patients including surgery, hospital admissions and immobilization, the presence of an indwelling central catheter, chemotherapy, use of erythropoiesis-stimulating agents (ESAs) and new molecular-targeted therapies such as antiangiogenic agents. (oncologynurseadvisor.com)
  • The molecular pathological hallmarks of arterial stroke and cerebral venous thrombosis. (frontiersin.org)
  • Deep venous thrombosis (DVT) occurs when a blood clot affects deeper, larger veins, such as those in the lower legs and thighs. (medbroadcast.com)
  • Anticoagulants Deep venous thrombosis (DVT) is clotting of blood in a deep vein of an extremity (usually calf or thigh) or the pelvis. (msdmanuals.com)
  • Anticoagulant treatment references Almost all patients with deep venous thrombosis (DVT) are given anticoagulants and in rare cases thrombolytics. (msdmanuals.com)
  • BACKGROUND: Clinicians confront numerous practical issues in optimizing the use of anticoagulants to treat venous thromboembolism (VTE). (cdc.gov)
Pulmonary1
  • Adult patients with confirmed cancer who had a new diagnosis of proximal lower-limb deep vein thrombosis or pulmonary embolism were enrolled in the trial. (the-hospitalist.org)
Antiplatelet agents3
  • In October 2021, ISTH assembled an international panel of content experts, patient representatives, and a methodologist to develop recommendations on anticoagulants and antiplatelet agents for patients with COVID-19 in different clinical settings. (nih.gov)
  • Based on drug class, the global placenta insufficiency treatment market can be segmented into antiplatelet agents and anticoagulants. (sbwire.com)
  • Antiplatelet agents, such as low molecular weight heparins, are generally preferred by doctors for treating placenta insufficiency as they have more pronounced antithrombotic activity. (sbwire.com)
Aspirin8
  • Aspirin and heparin are clearly indicated. (nih.gov)
  • The comparison of compression plus anticoagulant prophylaxis versus compression plus aspirin showed a nonsignificant reduction in PE and DVT in favor of the former group. (aafp.org)
  • Hallstrom is the lead author of a new study published in JAMA Surgery that found few patients developed a blood clot after surgery, and those patients on aspirin fared just as well as those on anticoagulants. (sciencedaily.com)
  • Over the past decade, surgeons have turned away from powerful anticoagulants and toward aspirin used in addition to nondrug improvements such as compression devices for thwarting clots. (sciencedaily.com)
  • and 13 percent took an aspirin/anticoagulant combination. (sciencedaily.com)
  • Yet neurologists outside Hadassah, including in various countries around the world who have joined the debate, argued that giving him aspirin and Plavix would have been enough and that the risk of brain hemorrhage posed by Clexane was five percent but too risky for a man of Sharon's age, weight and habits. (jpost.com)
  • Of 64 women, 29 had received aspirin and 35 aspirin plus heparin. (who.int)
  • Aspirin alone or in combination with heparin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage. (who.int)
Dabigatran1
  • Their advantages are that they are effective within several hours and thus do not require a period of overlapping treatment with heparin (bridging treatment), although edoxaban and dabigatran require at least 5 days of pretreatment with an injectable anticoagulant. (msdmanuals.com)
DOAC1
  • The Hospital Pharmacist can balance the antithrombotic benefit of the DOAC with its bleeding risk by recommending the appropriate dose of DOACs to physicians according to the patients' characteristics (age, weight, renal functions). (eahp.eu)
Platelet1
  • Heparin-induced thrombocytopenia is an immune mediated reaction, which may be secondary to heparin and causing platelet aggregation. (gponline.com)
DOACs2
Oral8
  • Coumarins are a class of oral anticoagulant drugs that act as antagonists to vitamin K. The mechanism of action is to interfere with the interaction between vitamin K and coagulation factors II, VII, IX, and X. Vitamin K acts as a cofactor at these levels. (medscape.com)
  • Oral anticoagulants. (bmj.com)
  • T here are very limited treatment options for these young patients, and no direct oral anticoagulant is currently approved for use in this setting. (jnj.com)
  • This trial examined for the first time whether a direct oral anticoagulant could alleviate the burden of blood clots in young patients, which would allow them to focus on recovering from their other health challenges," said Christoph Male, M.D., Department of Pediatrics, Medical University of Vienna, Vienna, Austria. (jnj.com)
  • The impact of an electronic alert to reduce the risk of co-prescription of low molecular weight heparins and direct oral anticoagulants. (ahrq.gov)
  • Novel oral anticoagulants (NOACs) are an emerging development in the treatment and prevention of VTE. (oncologynurseadvisor.com)
  • Recently, the development of novel oral anticoagulants (NOACs) that directly inhibit factor Xa or thrombin is a milestone achievement in the prevention and treatment of VTE. (oncologynurseadvisor.com)
  • Background The American College of Chest Physicians Clinical Practice Guideline on the Perioperative Management of Antithrombotic Therapy addresses 43 Patients-Interventions-Comparators-Outcomes (PICO) questions related to the perioperative management of patients who are receiving long-term oral anticoagulant or antiplatelet therapy and require an elective surgery/procedure. (bvsalud.org)
Injections3
  • For these patients, physicians manipulate adult dosage forms of these older anticoagulants, many of which require injections and regular laboratory monitoring. (jnj.com)
  • Patients can get it over the counter for pennies, while the other anticoagulants require monitoring, injections, frequent dose adjustments and are extremely expensive. (sciencedaily.com)
  • Hadassah has official denied such claims, saying that the decision to prescribe twice-daily injections of Clexane, the low-molecular-weight heparin that thins the blood, was taken by a consensus of Hadassah physicians of the various specialties and that it was needed to prevent a recurrent and much more devastating ischemic stroke than that caused by the initial blood clot. (jpost.com)
Patients30
  • Patients with coronavirus disease 2019 (COVID-19) may realize additional benefits from heparins. (nih.gov)
  • It also remains to be demonstrated whether low-molecular-weight heparin is superior to standard heparin in this setting and which patients should undergo angiography. (nih.gov)
  • These drugs are especially being used for previously unmet needs, i.e., for patients with relapsed or refractory disease, high-risk cytogenetic or molecular abnormalities, or with comorbidities. (haematologica.org)
  • In a secondary analysis from the SWOG S1007 trial reported in JAMA Oncology, Reshma Jagsi, MD, DPhil, and colleagues found low rates of locoregional recurrence irrespective of the use of regional nodal irradiation in patients with favorable-risk, node-positive breast cancer receiving radiation. (ascopost.com)
  • The purpose of this study is to evaluate the response to treatment with Ribociclib and Letrozole in patients with low-grade serous cancer of the ovary, fallopian tube or peritoneum. (mayo.edu)
  • In order to prevent inclusion of patients with high-grade serous carcinoma, diagnosis of low-grade serous carcinoma will be verified as part of screening review by a gynecologic pathologist. (mayo.edu)
  • The purpose of this review is to provide a latest summary of biomarkers associated with endothelial cell activation in COVID-19 and offer mechanistic insights into the molecular basis of endothelial activation/dysfunction in macro- and micro-vasculature of COVID-19 patients. (nature.com)
  • There are no low-molecular-weight heparins or other anticoagulants approved for use in cancer patients undergoing chemotherapy, according to the FDA. (medscape.com)
  • patients with the other cancers (stomach, colon/rectum, bladder, or ovary) showed no significant benefit from the anticoagulant. (medscape.com)
  • The study found that the 1-year cumulative incidence of VTE was 9.5 percent in the breast cancer patients who received chemotherapy and had high genetic susceptibility, compared with 1.3 percent in the patients who did not receive chemotherapy and had lower genetic susceptibility. (nursingcenter.com)
  • In New Zealand it is estimated that 40% of patients with AF who are likely to benefit from an anticoagulant are not prescribed one. (bpac.org.nz)
  • Patients with the lowest CHA 2 DS 2 -VASc risk scores for their sex (zero for males, one for females) should not use an anticoagulant. (bpac.org.nz)
  • such patients are unlikely to benefit from anticoagulant (or antiplatelet) use and be exposed to unnecessary risks. (bpac.org.nz)
  • This audit identifies patients with AF in order to assess whether their use of anticoagulants is appropriate for their current stroke risk. (bpac.org.nz)
  • Despite their health benefits, anticoagulants place patients at high risk for medication-related harm. (ahrq.gov)
  • This article will review the limitations of unfractionated heparin and the mechanisms by which low-molecular-weight heparin overcomes these limitations, as well as the results of recent trials involving low-molecular-weight heparin in the management of patients with acute coronary syndromes. (mcmaster.ca)
  • Rates of asymptomatic DVT range from less than 10 percent in low-risk patients (e.g., those having minor surgery) to 40 to 80 percent in high-risk patients (e.g., those having hip or knee arthroplasty). (aafp.org)
  • Until EINSTEIN-Jr, only one small randomized trial had been published evaluating the use of standard anticoagulants in pediatric patients with VTE. (jnj.com)
  • The recommendation of using low molecular weight heparins as the primary anticoagulants for patients with malignancies has been practiced. (helsinki.fi)
  • These days, most patients have a generally low risk of blood clots after knee replacement for a number of reasons. (sciencedaily.com)
  • That was true for 1.42 percent of anticoagulant patients, according to the Michigan study. (sciencedaily.com)
  • This retrospective study included 116 patients over the age of 18 who received anticoagulant treatment for at least 3 months and presented for treatment discontinuation to the Atatürk University Research Hospital Chest Diseases Outpatient Clinic between January 2015 and September 2019. (researchsquare.com)
  • When discontinuing treatment in PTE, the evaluation of symptoms, D-dimer level, echocardiography (ECHO), and bilateral lower extremity color Doppler ultrasound (US) findings can help identify patients who should be considered at risk of recurrence. (researchsquare.com)
  • We retrospectively reviewed the data of patients diagnosed with PTE who had received the required duration of anticoagulant therapy according to their risk factors and presented for treatment discontinuation to the Atatürk University Chest Diseases Outpatient Clinic between January 2015 and September 2019. (researchsquare.com)
  • Anticoagulants and thromboprophylaxis can protect patients from this adverse effect. (oncologynurseadvisor.com)
  • This phase II trial studies molecular profiling-based assignment of cancer therapy (MPACT) in treating patients with solid tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). (mycancergenome.org)
  • OBJECTIVE: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians and other health care professionals in their decisions about the use of anticoagulants in the management of VTE. (cdc.gov)
  • RESULTS: The panel agreed on 25 recommendations and 2 good practice statements to optimize management of patients receiving anticoagulants. (cdc.gov)
  • The objective was to determine if high birth weight or higher early life ultraviolet (UV) radiation exposure would be associated with increased risk of melanoma in young patients. (cdc.gov)
  • The guidelines now have made it clear that unfractionated heparin is preferred for patients with STEMI who are going for emergent catheterization. (medscape.com)
Thromboprophylaxis1
Concomitant1
  • Hospital Pharmacists can minimize the risk of bleeding of a patient on an anticoagulant by acting and modifying the reversible risk factors for bleeding such as hypertension, concomitant medications, alcohol misuse or patient's poor adherence to anticoagulants (overdose). (eahp.eu)
Enoxaparin1
  • The investigators hypothesize that when enoxaparin is dosed by maternal weight and administered twice daily, the anti-factor Xa level would more frequently achieve prophylactic levels when compared to taking a fixed 40 mg of the drug daily. (druglib.com)
Dose7
  • The dose is weight adjusted. (medscape.com)
  • Implementation was associated with a lower probability of MAEs (particularly omission errors and wrong dose errors), but impact would likely be greater with increased compliance with barcode scanning. (ahrq.gov)
  • The objective of this study is to assess what proportion of women achieve the desired anti Xa level with the fixed daily dose versus twice daily weight based dosing (0. (druglib.com)
  • Delivering a clot-dissolving drug directly into the clot-instead of having it circulate through the bloodstream via standard intravenous delivery-allows the use of a lower dose, which decreases the risk of bleeding elsewhere in the body. (harvard.edu)
  • If you are hospitalized for some reason, ask your doctors and nurses to make sure you are receiving measures-such as wearing special stockings or getting low-dose heparin-to prevent blood clots. (harvard.edu)
  • The dose-response relationship is not linear and the anticoagulant effect increases disproportionately as doses are increased, so heparin therapy requires intensive monitoring. (gponline.com)
  • If the patient is receiving heparin by intermittent injection, the sample should be drawn 30-60 minutes before the next dose, while, if the patient is receiving a continuous heparin infusion, the sample can be drawn at any time. (medscape.com)
Patient's1
  • The aPTT is considered a more sensitive version of the PTT and is used to monitor the patient's response to heparin therapy. (medscape.com)
20221
Clot4
  • Heparin prevents reaccumulation of a clot after a spontaneous fibrinolysis. (medscape.com)
  • Deep vein thrombosis (DVT) is a condition in which a blood clot develops in the deep veins, usually in the lower extremities. (cdc.gov)
  • But anticoagulants can't quickly dissolve a clot that has already formed. (harvard.edu)
  • Ultrasound of the left lower extremity reveals a clot in the peroneal vein. (emra.org)
Deep vein throm1
  • Deep-vein thrombosis is initially treated with an anticoagulant. (harvard.edu)
XARELTO1
  • There were no major bleeding events in the XARELTO ® group, and two major bleeding events in the standard anticoagulant group. (jnj.com)
APTT1
  • The activated partial thromboplastin time (APTT) has been used to monitor therapeutic doses of unfractionated heparin. (gponline.com)
Medication1
  • Anticoagulant medication errors in hospitals and primary care: a cross-sectional study. (ahrq.gov)
20192
  • The lowest weekly event rate occurred during the national lock down in spring 2020 but a similar trend occurred also in 2019 suggesting that the effect may not be linked to social distancing measures. (bvsalud.org)
  • The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is responsible for coronavirus disease 2019 (COVID-19) resulted in systemic inflammatory response and imbalance between homeostatic mechanisms of procoagulant and anticoagulant. (who.int)
Clots2
  • The critical care specialists who make up the American College of Chest Physicians favor heparin to reduce the risk of blood clots, while the American Academy of Orthopaedic Surgeons guidelines state that no one drug is better than another for preventing clots. (sciencedaily.com)
  • Anticoagulants can stop a DVT from getting larger and can prevent new clots from forming. (harvard.edu)
Complications1
  • Aucune différence significative en termes de complications prénatales et maternelles n'a été constatée entre les deux groupes. (who.int)
Pregnancy1
Extremity1
  • You are a third-year resident working in the ED one night when the following patient arrives: a 65-year-old man with a five-year history of type 2 diabetes mellitus and a less than one-year history of multiple myeloma presenting with a complaint of left lower extremity pain and paresthesias in his hands and feet. (emra.org)
Clinical trials1
  • 50% in the 1930s to 10-15% currently, and even lower in some clinical trials. (nih.gov)
Acute2
  • Although unfractionated heparin is widely used in the treatment of acute coronary syndromes, it has several pharmacokinetic, biophysical, and biological limitations. (mcmaster.ca)
  • In acute situations, concurrent administration of heparin and daily monitoring of INR for the first few days are recommended. (gponline.com)
Ischemic2
  • Did Hadassah doctors provide Sharon with "too much treatment" in the form of anticoagulant drugs after his first - mild, ischemic - stroke? (jpost.com)
  • For a more quantitative approach less concerned with molecular biology, see Quantifying Ischemic Damage for Cryonics Rescue . (benbest.com)
Injection1
Extremities1
  • You all know this disease, which is progressive atrophy and paralysis of muscles first in the lower and then in the upper extremities, and accompanying cardiomyopathy. (medscape.com)